Roger Hawley Sells 35,000 Shares of Zogenix, Inc. (NASDAQ:ZGNX) Stock

Zogenix, Inc. (NASDAQ:ZGNX) Director Roger Hawley sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total transaction of $1,564,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

ZGNX stock traded down $1.60 during trading on Friday, reaching $36.45. The company had a trading volume of 394,971 shares, compared to its average volume of 412,921. Zogenix, Inc. has a twelve month low of $10.05 and a twelve month high of $45.85. The stock has a market capitalization of $1,303.31, a PE ratio of -9.07 and a beta of 1.68.

How to Become a New Pot Stock Millionaire

Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings results on Tuesday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.17). During the same period in the prior year, the firm earned ($0.95) EPS. sell-side analysts anticipate that Zogenix, Inc. will post -3.12 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of ZGNX. Voya Investment Management LLC raised its position in Zogenix by 13.5% during the 2nd quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock worth $205,000 after buying an additional 1,686 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Zogenix during the 3rd quarter worth approximately $226,000. Sterling Capital Management LLC purchased a new position in Zogenix during the 3rd quarter worth approximately $237,000. Teacher Retirement System of Texas purchased a new position in Zogenix during the 4th quarter worth approximately $409,000. Finally, Raymond James & Associates purchased a new position in Zogenix during the 4th quarter worth approximately $460,000.

A number of analysts recently commented on ZGNX shares. BidaskClub upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, January 27th. Leerink Swann lifted their target price on shares of Zogenix from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Mizuho reiterated a “buy” rating and issued a $51.00 target price on shares of Zogenix in a research note on Thursday, February 1st. Finally, ValuEngine upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Eight research analysts have rated the stock with a buy rating, Zogenix has a consensus rating of “Buy” and an average target price of $53.20.

COPYRIGHT VIOLATION WARNING: “Roger Hawley Sells 35,000 Shares of Zogenix, Inc. (NASDAQ:ZGNX) Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/roger-hawley-sells-35000-shares-of-zogenix-inc-zgnx-stock.html.

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply